Pieris Pharmaceuticals (NASDAQ:PIRS) has been given a $9.00 price objective by investment analysts at HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 53.85% from the company’s previous close.
Separately, ValuEngine cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $9.00.
Pieris Pharmaceuticals (PIRS) traded up $0.21 on Wednesday, reaching $5.85. 371,200 shares of the company traded hands, compared to its average volume of 615,023. Pieris Pharmaceuticals has a 1-year low of $1.36 and a 1-year high of $6.65.
A number of large investors have recently modified their holdings of PIRS. Renaissance Technologies LLC bought a new stake in Pieris Pharmaceuticals during the 1st quarter worth about $661,000. Schwab Charles Investment Management Inc. bought a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $292,000. Rhumbline Advisers bought a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $184,000. State of Wisconsin Investment Board bought a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $132,000. Finally, Bank of New York Mellon Corp bought a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $359,000. 50.45% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/12/20/pieris-pharmaceuticals-pirs-pt-set-at-9-00-by-hc-wainwright.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.